Skip to content

Compare medicines

Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.

Attribute
In shortBlocks testosterone production for advanced prostate cancer; taken with prednisolone.Tablet that blocks testosterone in prostate cancer.
Body systemCancerCancer
Drug classAndrogen synthesis inhibitorsAndrogen receptor inhibitors
SupplyPrescription onlyWHO essential medicinePrescription only
Main usesMetastatic prostate cancerAdvanced and metastatic prostate cancer, High-risk non-metastatic prostate cancer
How it worksSwitches off testosterone production.Stops testosterone driving prostate cancer growth.
Starts workingDepends on the cancer and regimen—
Half-lifeAbout 12–15 hoursAbout 6 days
Typical adult doseDosed by your cancer team according to the treatment protocol.160 mg once a day.
FormsTabletCapsule, Tablet
Common side effectsSwollen ankles, High blood pressure, Low potassium, Hot flushes, Joint achesFatigue, Hot flushes, High blood pressure, Falls
Serious side effectsLiver toxicity, Heart failure, Adrenal insufficiencySeizures, Heart events, Fractures
Don't take ifSevere liver impairment; Women—
AlcoholUsually no problem in moderation. No specific interaction.—
PregnancyUsually avoidedNot for use in women.Usually avoidedCondoms required with a pregnant partner.
BreastfeedingUsually avoidedNot applicable to women.—
In use since—2012
Brand namesUnited States: Zytiga, YonsaUnited Kingdom: ZytigaIndia: Abiraterone (generic), Zytiga, AbiraproUnited States: XtandiUnited Kingdom: XtandiIndia: Xtandi, Bdenza
Legal statusUnited States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM)India: Schedule H—
ATC codeL02BX03L02BB04

Taken together

  • ModerateAbiraterone + Enzalutamide: Reduced effect

    Enzyme induction lowers levels of this medicine, which may stop it working.

Open in the interaction checker